Drug Eluting Stent dan pemakaian Off-label

  • Otte J Rachman Departemen Kardiologi dan Kedokteran Vaskular, FKUI. Pusat Jantung Nasional Harapan Kita, Jakarta
DOI: https://doi.org/10.30701/ijc.v29i2.191

Abstract

Revaskulasisasi koroner dengan PCI (Percutaneous Coronary Intervention) merupakan suatu cara yang sudah diterima sebagai alternatif bedah dalam mengatasi Penyakit Jantung Koroner (PJK). Pemakaian Stent mempertinggi keberhasilan PCI namun tidak berhasil menghilangkan “the Achilles heel of PCI” berupa restenosis yang mengganjal keberhasilan jangka dekat dan panjang. Stent dengan penyalut obat (DES) berhasil mengurangi insidens restenosis menjadi amat kecil sehingga meningkatkan keberhasilan PCI dalam mengatasi PJK.
Pemakaian DES kemudian amat meningkat dan menimbulkan kejadian fatal yang disebabkan karena kematian karena terjadinya trombosis. Sejak FDA di Amerika sekitar bulan Februari 2003 mengizinkan pemakaian DES dengan obat Sirolimus dan Paclitaxel, pemakaian DES diindikasikan hanya pada penderita2 tertentu dengan lesi de novodengan panjang < 30 mm dan diameter antara 2.5 sampai 3.5 mm sesuai dengan data2 yang didapat pada penelitian awal.

Downloads

Download data is not yet available.

References

Stone GW, Ellis SG, Cannon L, dkk. Comparison of polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA. 2005; 294: 1215-1223.

Aribowo DD, Tobing D, Sunanto Ng, Munawar M, Soerianata S. Implantasi drug-eluting stent atas indikasi off-label: Pengala-man dan luaran klinis di Pusat Jantung Nasional Harapan Kita. J Kardiol Indones. 2008;

Applegate RJ, Sacrinty MT, Kutcher MA, dkk. Off-label stent therapy: 2-year comparison of drug eluting versus bare metal stents. J Am Coll Cardiol. 2008; 51: 607-614.

Pfisterer ME for the BASKET-LATE Investigators. Late clinical events related to late stent thrombosis after stopping clopidogrel: Prospective randomized comparison between drug-eluting versus bare metal stenting. Abstract 422-American College of Cardiol-ogy 55th Annual Scientific Meeting; March 11-14, 2006. Atlanta Georgia.

Joner M,Finn AV,Farb, dkk. Pathology of drug eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol.2006; 48: 193-202.

Lee SW, Park SW, Hong MK, dkk. Triple versus dual antipletelt therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol. 2005; 46: 1833-1837.
Views & Downloads
Abstract views: 5160   
PDF (Bahasa Indonesia) downloads: 2903   
How to Cite
Rachman, O. (1). Drug Eluting Stent dan pemakaian Off-label. Indonesian Journal of Cardiology, 29(2), 80-81. https://doi.org/10.30701/ijc.v29i2.191
Issue
Vol. 29, No. 2 Mei - Agustus 2008
Section
Comments

Authors who publish with this journal agree to the following terms:

    • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).